Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Paternal overweight, obesity contribute to LGA risk after frozen embryo transfer

31 May 2020

A high body mass index (BMI) among fathers appears to be a risk factor for a large for gestational age (LGA) outcome after frozen embryo transfer (FET), according to a study.

Researchers looked at 7,908 singleton newborns, among whom 284 (3.6 percent) had paternal BMI in the underweight category, 4,678 (59.2 percent) in the normal category, 2,585 (32.7 percent) in the overweight category, and 361 (4.6 percent) in the obesity category.  

The mean paternal BMI was 24.12 kg/m2. Men with normal weight were slightly older (33.86 5.29 years) than those who were underweight but were slightly younger than those in the higher BMI categories. Men who were overweight or obese were more likely to be smokers than those who were of normal weight.

As earlier indicated, the proportion of LGA infants was significantly higher in the paternal overweight and obesity categories than in the paternal underweight category. The proportion was also higher in the paternal overweight category but lower in the paternal underweight category than in the normal-weight reference.

Meanwhile, the rates of foetal macrosomia were higher in the paternal overweight than in the normal weight category. Z-scores (gestational age- and sex-adjusted birthweight) were significantly higher among infants with overweight or obese fathers than among those whose fathers had normal weight.

Multiple linear regression model revealed a positive association between paternal BMI and newborn birthweight.

Additional studies with large sample sizes are needed to examine whether the differences in birthweight observed in the current study have implications for the risk of complications during the foetal and neonatal periods and many diseases in adulthood, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.